Included in the formulation
АТХ:S.01.G.X Other antiallergic drugs
S.01.G.X.05 Lodoxamide
Pharmacodynamics:Stabilization of cell membranes, possibly through the transport of Ca ions2+ in the period of antigenic stimulation.
Pharmacokinetics:Absorption is very low. With topical application, the drug is not detected in the blood plasma. Half-life (with oral administration) - 8.5 hours. Elimination is carried out mainly by the kidneys.
Indications:Allergic conjunctivitis, keratoconjunctivitis (seasonal, year-round and others).
VII.H10-H13.H10.1 Acute atopic conjunctivitis
VII.H10-H13.H10.4 Chronic conjunctivitis
VII.H15-H22.H16.2 Keratoconjunctivitis
Contraindications:Hypersensitivity.
Carefully:Pregnancy, breast-feeding, children's age (up to 2 years).
Pregnancy and lactation:In experiments on rats and rabbits, there was no toxic effect on fetal development. There is no information on the penetration into breast milk.
FDA recommendation category B.
Dosing and Administration:Adults and children over 2 years - 1-2 drops in each eye 4 times a day at a constant interval.
Side effects:Burning, paresthesias, pruritus conjunctival hyperemia eye irritation, foreign body sensation in the eye, lacrimation, blepharitis, keratitis; edema, pain in the eye, excessive eye fatigue.
Chemosis, deposition of crystals and ulceration of the cornea, hemorrhage in the anterior chamber of the eye.
Systemic reactions: excessive fatigue, visual impairment, headache, dizziness, drowsiness, dyspepsia, dryness of the nasal mucosa, allergic reactions (itching, heat, rash).
Overdose:Not described.
Treatment is symptomatic.
Interaction:Not described.
Special instructions:On the effectiveness of keratoconjunctivitis is superior to cromoglycic acid.
With spring conjunctivitis reduces the number of inflammatory cells in the lacrimal fluid.
Equal effectiveness of levocabastine (blocker H1receptors).
With spring keratoconjunctivitis reduces the increased content of leukotrienes in the lacrimal fluid.
With single inhalations of lodoxamid in doses of 0.1 and 1.0 mg, patients with bronchial asthma suffer large inhalation doses of the allergen, but there is no evidence of a long-term positive effect on the treatment of allergic asthma.